程序性死亡配体1与甲状腺癌相关性研究进展

Research progress of correlation between PD-L1 and thyroid cancer

程序性死亡配体1(PD-L1)属于免疫球蛋白超家族的Ⅰ型跨膜蛋白,广泛表达于各种组织细胞上,参与机体自身免疫、移植免疫以及肿瘤免疫等免疫调节过程。同样,PD-L1也可在甲状腺癌细胞上显著表达,在其与程序性死亡受体-1(PD-1)相互作用时可抑制CD8T细胞应答,传递负性调控信号,导致肿瘤抗原特异性的T细胞衰竭或功能障碍,使肿瘤细胞逃脱机体的免疫监视,从而促进肿瘤的发生发展。文章综述了PD-L1与甲状腺癌相关性的研究进展,研究PD-L1在甲状腺癌中表达的作用机制,从而为治疗甲状腺癌寻求有效的治疗靶点。

Programmed cell death 1-ligand 1(PD-L1)is type I transmembrane protein that belongs to immunoglobulin superfamily,PD-L1 is widely expressed in surface of various cells and is involved in auto-immunomodulatory processes,transplantation immunity and tumor immunity.Morever,thyroid cancer cells can significantly express PD-L1 can also bein,which can inhibit the response of CD8 T cells and transmit negative regulatory signals when interacting with programmed death receptor-1(PD-1).It leads to tumor antigen-specific T cell failure or dysfunction,what makes tumor cells escape immune surveillance,so as to promote the occurrence and development of tumor.The purpose of this review was to discuss the relationship between PD-L1 and thyroid carcinoma.